The Australian medical landscape is abuzz with the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor agonist showing impressive results in early trials for addressing obesity. This https://socialmarkz.com/story12467040/retatrutide-australia-a-potential-hope-for-weight-management